Search

everythinglearnresearchcommunity

for

Search:↓

OP has been using daily oral finasteride 1.25mg for 5 months with noticeable progress and no side effects. They chose this dosage by cutting 5mg pills into quarters due to cost.

The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

The user is concerned about low DHT levels due to using saw palmetto in Foligain supplements and is considering trying finasteride. They seek advice on whether finasteride will also lower DHT and how to manage DHT levels.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The user is considering starting dutasteride (DUT) 0.5mg for hair loss due to lack of access to finasteride and is concerned about potential side effects. They seek guidance on whether to begin this treatment.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

Store finasteride powder in a cool, dry place. RU58841 needs to be stored in the freezer.

A user is seeking a prescription for DUT (Dutasteride) after limited success with finasteride and minoxidil for hair loss. They are advised to explore telehealth services for potential prescriptions.

The user is experiencing dry, frizzy hair despite using dutasteride and finasteride for hair loss, which may be due to reduced sebum production. Suggestions include using nourishing conditioners, hair oils, and styling products to manage frizz, especially for curly hair.

Dutasteride is effective for hair loss but may cause side effects like decreased sperm count, which might not fully recover after stopping. Users discuss balancing dosages to minimize side effects while maintaining benefits.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The conversation discusses severe hair shedding and thinning, with the original poster using finasteride, oral minoxidil, and other supplements without improvement. The discussion highlights the possibility of telogen effluvium and the importance of addressing potential underlying health issues, such as stress and gut health, rather than assuming diffuse unpatterned alopecia (DUPA).

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

User shared 6-month hair loss treatment update with Dut 3x/week, oral min, and dut+prp mesotherapy. Experienced positive results, no side effects, and recommends the regimen.

A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

The user experienced side effects from finasteride and is considering switching to dutasteride, while also using pyrilutamide to protect hair follicles. They are seeking advice on whether to add RU58841 to their regimen.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A 20-year-old is experiencing severe hair loss and is considering using dutasteride and finasteride, worried about potential side effects. They feel depressed and isolated due to hair loss, and are exploring options like hair transplants and hair systems but are hesitant about faking it.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.